Navigation Links
New Jersey Center for Prostate Cancer & Urology Among First in Nation to Treat Advanced Prostate Cancer Patients with PROVENGE
Date:5/16/2011

MAYWOOD, N.J., May 16, 2011 /PRNewswire/ -- New Jersey Center for Prostate Cancer & Urology is among the first sites in the nation to treat advanced prostate cancer patients with PROVENGE® (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies.  PROVENGE was approved by the U.S. Food and Drug Administration (FDA) for the treatment of men with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer and is made by Dendreon Corporation.

"PROVENGE is a revolutionary new treatment that may lead to similar personalized therapies in other cancer types," said Dr. Vincent Lanteri of NJ Center for Prostate Cancer & Urology. "We are pleased to have a new option to offer our patients and to be selected as one of the first facilities treating men with this important new therapy."

"PROVENGE allows patients to use their own cells to help fight cancer," said Dr. Michael Esposito.  "Patients with advanced prostate cancer now have a new option to prolong their lives.  I'm very excited about this and have high hopes for it."

PROVENGE is an autologous (made from a patient's own immune cells) cellular immunotherapy designed to stimulate a patient's immune system to identify and target prostate cancer cells. Each dose is manufactured specifically for each patient using his immune cells.

Individuals interested in learning whether PROVENGE is an appropriate treatment option should contact New Jersey Center for Prostate Cancer & Urology 201-487-8866 or call 1-877-336-3736.

About New Jersey Center for Prostate Cancer & Urology

The doctors of New Jersey Center for Prostate Cancer and Urology are undisputed experts in the field and have been recognized as 'Top Doctors' by New Jersey Monthly and New York Magazine and selected by Castle Connolly as 'Top Doctors for Cancer' in the country.  With locations in Northern and Central New Jersey, the practice offers patients needing prostate cancer or urological treatment easy access to state-of-the-art urological care close to home.  Offices are located at 255 W. Spring Valley Avenue, Maywood, NJ, at Holy Name Medical Center 718 Teaneck Road, Teaneck NJ, and at Monmouth Medical Center, 255 Third Avenue, Long Branch, NJ.  For more information about New Jersey Center for Prostate Cancer and Urology call (201) 487-8866 or visit www.RoboticUrology.com.


'/>"/>
SOURCE New Jersey Center for Prostate Cancer & Urology
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharma Elite to Unveil Latest Industry News/Program Agenda with 70+ Expert Speakers at Exclusive Event: Pharma CI Conference, September 13-14, 2011 in New Jersey
2. NeoStems Subsidiary Progenitor Cell Therapy Receives FACT Accreditation for Its New Allendale, New Jersey Manufacturing Facility
3. Bayer HealthCare Selects the State of New Jersey for East Coast Site Consolidation
4. Mesothelioma Litigation Attorney, Christopher Placitella to Lead Expert Panel on Mass Tort Litigation in New Jersey
5. Pharma ChemOutsourcing Targets BioNJ, PA Bio, MassBio, BayBio, SoCalBio, and NY Biotechnology Association Member Companies for September 2011 Show in New Jersey
6. Osteotechs Plexur M® Technology Wins Thomas Alva Edison Patent Award from the New Jersey Research and Development Council
7. Collagen Matrix, Inc. Expands Operations and Moves Corporate Headquarters to Oakland, New Jersey
8. First Live Web Chat by New Jerseys Princeton HealthCare System Focuses on Womens Health
9. Hospital Room of the Future Debuts in New Jersey
10. Curemark Opens Autism Trials at New Jersey Site
11. Big Pharma Chemists Turning Out in Large Numbers for ChemOutsourcing Extravaganza Event on September 14-16, 2010 at Jersey Shore Beach Resort
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), ... Forecasts, 2014 - 2025" report to their offering. ... The Latin American pharmaceutical ... billion by 2025 Low drug registration cost in ...
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray product ... a healthy CAGR during the forecast period Mobile ... the global digital mobile X-Ray devices market, which is estimated ... 2017, expanding at a CAGR of 7% over the forecast ... opportunity of more than US$ 100 Mn in 2017 over ...
Breaking Medicine Technology:
(Date:4/24/2017)... DC (PRWEB) , ... April 24, 2017 , ... The ... recognized during ATA 2017: Telehealth 2.0 — the American Telemedicine Association’s annual conference, on ... Santana Telehealth Project for using telemedicine to improve the lives of the poor and ...
(Date:4/24/2017)... IL (PRWEB) , ... April 24, 2017 , ... Today, Bright Pink , a ... in young women, names a new CEO. , Bright Pink is proud to announce ... she would be moving to a new role as Chairman of the Board and ...
(Date:4/24/2017)... Raton, Florida (PRWEB) , ... April 24, 2017 ... ... develops a variety of unique liquid food supplements, announced its popular products are ... nutritional products. , ALP Nutrition® prioritizes the use of premium natural ingredients ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... (CDC), rising prescription opioid overdose deaths now claim the lives of 62 Americans ... civil case filings against drug manufacturers, distributors, pharmacies and prescribers by more than ...
(Date:4/24/2017)... ... 24, 2017 , ... As a former supermodel known for her timeless beauty, ... for single women is that she put all the words in her new book, ... insight, personal experiences and sparkling sense of humor have inspired her to write a ...
Breaking Medicine News(10 mins):